ED Pde 5i denied as non-formulary by Cigna?

Cigna's specific coverage criteria for ed pde5i are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Your PDE5 Inhibitor as Non-Formulary

A non-formulary denial means the specific PDE5 inhibitor your prescriber requested is not included on Cigna's drug formulary for your plan, or it sits at a tier level that requires additional justification before coverage is granted. Cigna's formulary typically includes at least one agent from the PDE5 inhibitor class; the denial often arises when the brand or specific generic requested differs from the preferred formulary agent, or when the plan design covers only a limited number of fills per period.

## Why This Denial Is Appealable

Non-formulary denials are appealable on two grounds. First, a formulary exception: if your prescriber documents that the preferred formulary alternative is clinically inappropriate for you — due to a contraindication, prior intolerance, inadequate response, or a patient-specific clinical reason — Cigna is generally required to consider covering the requested agent at a covered tier. Second, if Cigna changed its formulary mid-year in a way that moved your previously covered medication to a non-covered status, ACA regulations provide additional protections. Your appeal should be framed as a formulary exception request supported by clinical evidence.

## Federal Appeal Framework

Under ACA Section 2719, after exhausting Cigna's internal formulary exception and appeal process, you may request independent external review by an accredited IRO. ERISA Section 503 provides equivalent full-and-fair review protections for employer-sponsored plans. The external review window is approximately 4 months from the date of the final internal denial. Expedited review (72 hours) is available when clinical urgency is documented.

## Concrete Appeal Steps and Timeline

1. Identify the preferred formulary alternative(s) — ask Cigna or check your plan's formulary for which PDE5 inhibitor is preferred and at what tier. 2. Ask your prescriber to document the clinical reason the preferred agent is not appropriate for you specifically. 3. Submit a formulary exception request together with the internal appeal — in many cases these are combined into one submission. 4. Confirm the appeal deadline on your EOB or denial letter and file before it passes. 5. Escalate to external review if the internal exception and appeal are both denied.

## Documentation to Gather

• Diagnosis confirmation: Chart notes establishing the ED diagnosis and any relevant comorbidities.
• Prior medication trials: If you tried the preferred formulary agent and it was ineffective or not tolerated, document dates, dosing attempts, and outcomes.
• Clinical rationale for the specific agent: A prescriber letter explaining why the requested non-formulary agent is medically necessary for this patient and why the formulary alternative is not clinically equivalent.
• FDA prescribing label: Confirm the indication and any clinically relevant product-specific characteristics.
• Criteria-mapping table: Obtain Cigna's formulary exception criteria from the published policy, list each requirement, and document the chart fact that satisfies it.